Latest From Xencor Inc.
When approved therapies target the same antigens as the investigational bispecific antibody, FDA may request a comparative clinical trial, draft guidance notes.
Combining Editas’ CRISPR gene-editing technology with BlueRock’s pluripotent stem cell capabilities, the companies hope to leverage each other to create novel gene therapies for cancer, neurological, cardiovascular and autoimmune diseases.
Genentech will pay $120m up front to co-develop Xencor’s preclinical IL-15 candidate; deal also includes IL-15 R&D. Taiho licenses lung cancer candidate to Cullinan; Celgene and Triphase partner again.
Sanofi and Regeneron terminate the immuno-oncology partnership signed in 2015, but will continue to collaborate on Libtayo. Biogen signs a pair of partnerships in CNS disorders, with C4 and Skyhawk, and more deals from the first day of the J.P. Morgan conference.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Xencor Inc.
- Senior Management
Bassil I Dahiyat, PhD, Pres. & CEO
John Kuch, SVP, CFO
John R Desjarlais, PhD, SVP, Research & CSO
Jeremy Grunstein, PhD, VP, Bus. Dev.
- Contact Info
Phone: (626) 305-5900
111 W. Lemon Ave.
Monrovia, CA 91016
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.